NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	psoriasis
Date of first enrollment	09/07/2012
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : Secukinumab INN of investigational material : Secukinumab Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigational material : Subcutaneous injection

Outcome(s)

Primary Outcome	PASI 75, IGA
Secondary Outcome	PASI 50/75/90/100, IGA

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria	Completed the full study treatment period of 52 weeks in preceding phase III studies, and have been receiving secukinumab treatment during the maintenance phase of the preceding phase III studies, and show at least a partial response (PASI 50 or better) at Week 52 of the preceding phase III studies.
Exclude criteria	Ongoing use of prohibited psoriasis or non-psoriasis treatments. Other protocol-defined inclusion/exclusion criteria may apply.